Company intelligence / Profile preview
Xbiome
Shenzhen, Guangdong, Chinaxbiome.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Phase 2
01
Overview
Xbiome has advanced AI-driven microbiome therapeutics into early-stage clinical trials. Its FMT capsule candidate has reached IND submission with the FDA for graft-vs-host disease. The company acquired a live biotherapeutic product from Assembly Biosciences targeting mild-to-moderate ulcerative colitis, planning Phase Ib trials in both the US and China.
- Therapeutic areas
- OncologyEndocrinologyImmunologyGastroenterologyNeurology
- Modalities
- Live biotherapeutic products (LBPs)ProbioticsBiological products (including recombinant LBPs)Monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Assembly Biosciences Inc. – asset acquisition partnership for ulcerative colitis program
Beyond the preview
Go deeper on Xbiome.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xbiome.